FASCINATION ABOUT IL-2 THERAPY FOR MELANOMA

It's perfectly understood that IL-two is a pleiotropic cytokine positioned in the crossroads of T cell activation and regulation. Therefore, it is actually imperative to engineer an IL-2 molecule which is biased to effector cells bearing the intermediate affinity receptor, which include naïve and memory CD8+ T cells and NK cells, compared to Treg